Pfizer Inc. (PFE)
| Market Cap | 143.79B |
| Revenue (ttm) | 62.79B |
| Net Income (ttm) | 9.83B |
| Shares Out | 5.69B |
| EPS (ttm) | 1.73 |
| PE Ratio | 14.65 |
| Forward PE | 8.67 |
| Dividend | $1.72 (6.80%) |
| Ex-Dividend Date | Jan 23, 2026 |
| Volume | 42,966,317 |
| Open | 25.18 |
| Previous Close | 25.28 |
| Day's Range | 25.12 - 25.56 |
| 52-Week Range | 20.92 - 27.69 |
| Beta | 0.43 |
| Analysts | Hold |
| Price Target | 27.18 (+7.47%) |
| Earnings Date | Feb 3, 2026 |
About PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral pr... [Read more]
Financial Performance
In 2024, Pfizer's revenue was $63.63 billion, an increase of 6.84% compared to the previous year's $59.55 billion. Earnings were $8.03 billion, an increase of 279.00%.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for PFE stock is "Hold." The 12-month stock price target is $27.18, which is an increase of 7.47% from the latest price.
News
Gordian Bio Announces Research Collaboration with Pfizer to Accelerate In Vivo Target Discovery in Obesity
SAN FRANCISCO--(BUSINESS WIRE)-- #biotech--Gordian Bio Announces Research Collaboration with Pfizer to Accelerate In Vivo Target Discovery in Obesity.
Trial Date Has Been Set in MDL against Pfizer for Depo-Provera Overseen by Levin Papantonio
PENSACOLA, Fla.--(BUSINESS WIRE)--At a Case Management Conference in the Multi District Litigation against Pfizer Inc. (NYSE:PFE), the Honorable M. Casey Rodgers set a date for the first Trial, which ...
America's new vaccine doctrine for children replaces data with dogma
In just a few weeks, the U.S. went from a “quiet” recalibration of a single vaccine recommendation to a wholesale retreat from the basic architecture of childhood immunization. That shift is being sol...
Cartography Biosciences and Pfizer to Collaborate on the Discovery of Tumor-Selective Antigens
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cartography Biosciences, Inc., a biotechnology company advancing a differentiated pipeline of antibody-based cancer therapies, today announced a strategic...
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at...
Pfizer 2026: The Reset Year
Pfizer Inc. enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution, despite an aggressive strategic repositioning. The $10 billion Metsera acquisition immedi...
3 ultra-high-yield stocks to consider for $300 of dividend income in 2026
Generating meaningful dividend income from modest capital requires disciplined stock selection and a clear mathematical framework. An allocation of $2,670 distributed equally across three carefully ve...
Exclusive: Drugmakers raise US prices on 350 medicines despite pressure from Trump
Drugmakers plan to raise U.S. prices on at least 350 branded medications including vaccines against COVID, RSV and shingles and blockbuster cancer treatment Ibrance, even as the Trump administration p...
Chevron, Kimberly-Clark Among 16 Companies To Kick Off 2026 With Annual Dividend Increases In January
Chevron (CVX) is expected to extend its dividend growth streak to 39 years, but with a muted 3–4% increase amid lower oil prices. CVX's earnings remain under pressure from declining oil prices despite...
Pfizer says patient dies after receiving hemophilia drug in trial
A patient who was being treated with Pfizer's hemophilia drug, Hympavzi, as part of a long-term study died after experiencing serious side effects, the company said.
Pfizer Isn't Dead Money, Pipeline Execution Can Spark A Rebound
Pfizer (PFE) remains materially undervalued, with a forward yield near 7% and a Buy rating maintained despite recent underperformance and guidance revisions. PFE's discounted valuation reflects worryi...
Pfizer Invites Public to View and Listen to Webcast of February 3 Conference Call with Analysts
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EST on Tuesday, ...
Pfizer Plays Catchup In Obesity Market, Licenses Weight-loss Drug From Fosun
Playing catch-up in the anti-obesity business, Pfizer has bought global rights to an oral weight-loss drug from Fosun Pharma in another big licensing deal
AbbVie, several other pharma companies near MFN deal with Trump, sources say
AbbVie and several other drugmakers are expected to announce on Friday agreements with the U.S. government to lower certain prescription drug prices and meet other demands made by President Donald Tru...
Pfizer Stock Can Sink More. Here Is How
Pfizer (PFE) is encountering threats. Even the most prominent names aren't immune.
Pfizer, Merck Are Boring Again — And That's Exactly Why 2026 Investors Are Circling Back
Pfizer Inc (NYSE: PFE) and Merck & Co Inc (NYSE: MRK) aren't exciting stocks anymore — and after a bruising reset, that's starting to look intentional. Pfizer's stock has been back in focus this month...
PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
PADCEV plus Keytruda is the first and only regimen without platinum-based chemotherapy to improve event-free and overall survival when used before and after surgery in cisplatin-eligible patients with...
Pfizer Inc. (PFE) Q4 2026 Guidance Call Transcript
Pfizer Inc. (PFE) Q4 2026 Guidance Call Transcript
Pfizer falls on disappointing guidance
CNBC's Annika Kim Constantino reports on Pfizer's 2026 guidance.
Pfizer's modest 2026 outlook shows its big investments will take time to pay off
Pfizer forecast modest 2026 guidance as it looks to counter waning Covid product sales and declines from older drugs with longer-term investments in its pipeline. The company expects adjusted profit o...
Here's why Pfizer is revising its revenue forecasts
The drugmaker revised its revenue guidance for 2025, saying it now expects $62 billion in revenue for the year.
Pfizer Stock Edges Higher on 2026 Guidance. Expect a Rough Year for Covid Vaccine Sales.
Pfizer expects revenue and earnings to fall in 2026.
Pfizer Expects Decline in Covid-19 Drug Demand to Hurt 2026 Earnings
Pfizer projected 2026 revenue of $59.5 billion to $62.5 billion and adjusted earnings of $2.80 to $3 a share. Wall Street is forecasting 2026 revenue of $61.6 billion and adjusted earnings of $3.05 a ...